Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Receivables (2018 - 2022)

Summit Therapeutics (SMMT) has disclosed Receivables for 4 consecutive years, with $349000.0 as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Receivables fell 82.88% year-over-year to $349000.0, compared with a TTM value of $349000.0 through Dec 2022, down 82.88%, and an annual FY2022 reading of $349000.0, down 82.88% over the prior year.
  • Receivables was $349000.0 for Q4 2022 at Summit Therapeutics, up from $140000.0 in the prior quarter.
  • Across five years, Receivables topped out at $4.1 million in Q3 2020 and bottomed at $140000.0 in Q3 2022.
  • Average Receivables over 4 years is $1.3 million, with a median of $1.1 million recorded in 2021.
  • The sharpest move saw Receivables skyrocketed 515.71% in 2021, then tumbled 93.91% in 2022.
  • Year by year, Receivables stood at $541000.0 in 2019, then plummeted by 38.82% to $331000.0 in 2020, then surged by 515.71% to $2.0 million in 2021, then crashed by 82.88% to $349000.0 in 2022.
  • Business Quant data shows Receivables for SMMT at $349000.0 in Q4 2022, $140000.0 in Q3 2022, and $1.3 million in Q2 2022.